Longboard Pharmaceuticals (LBPH) Stock Analysis

What Longboard Pharmaceuticals does

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm committed to advancing innovative treatments for neurological conditions. Its primary drug candidate, LP352, is currently progressing through a Phase 1b/2a clinical trial, aimed at managing seizures associated with developmental and epileptic encephalopathies. The company also boasts preclinical pipeline candidates, LP659 and LP143, designed to tackle a range of neurological diseases. Incorporated in 2020, the company, formerly known as Arena Neuroscience, Inc., adopted its current name, Longboard Pharmaceuticals, Inc., in October 2020. Its corporate headquarters are situated in La Jolla, California.

Key metrics

ETFs linked to LBPH

Broad-market and Healthcare sector ETFs an investor holding Longboard Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how LBPH fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Longboard Pharmaceuticals?

Longboard Pharmaceuticals trades under the ticker LBPH on NASDAQ.

Which exchange is LBPH listed on?

LBPH is listed on NASDAQ.

What sector does Longboard Pharmaceuticals operate in?

Longboard Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze LBPH in a portfolio?

PortView shows LBPH's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.